Search

Start Over Keyword IMMUNOTHERAPY

  • Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses

    Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses
    Authors:Veronique Bajzik, Benaroya Research InstituteHannah A. DeBerg, Benaroya Research InstituteNahir Garabatos, Benaroya Research InstituteBlake J. Rust, Benaroya Research InstituteKimberly K. Obrien, Benaroya Research InstituteQuynh-Anh Nguyen, Benaroya Research InstituteColin O'Rourke, Benaroya Research InstituteAlex Smith, Aimmune TherapeuticsAlex H. Walker, Benaroya Research InstituteCharlie Quinn, Benaroya Research InstituteVivian H. Gersuk, Benaroya Research InstituteMary Farrington, Virginia Mason Medical CenterDavid Jeong, Virginia Mason Medical CenterBrian Vickery, Emory UniversityDaniel C. Adelman, University of California San FranciscoErik Wambre, Benaroya Research Institute
    Date:2022
    Publisher:WILEY
    Publication Version:Author Accepted Manuscript (After Peer Review)

  • CD8+T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

    CD8+T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor
    Authors:Nataliya Prokhnevska, Emory UniversityMaria A Cardenas, Emory UniversityRajesh M Valanparambil, Emory UniversityEwelina Sobierajska, Emory UniversityBenjamin Barwick, Emory UniversityCaroline Jansen, Emory UniversityAdriana Reyes Moon, Emory UniversityPetra Gregorova, Emory UniversityLuke delBalzo, Emory UniversityRachel Greenwald, Emory UniversityMehmet Bilen, Emory UniversityMehrdad Alemozaffar, Emory UniversityShreyas Joshi, Emory UniversityCara Cimmino, Emory UniversityChristian Larsen, Emory UniversityViraj Master, Emory UniversityMartin Sanda, Emory UniversityHaydn Kissick, Emory University
    Date:2023
    Publisher:CELL PRESS
    Publication Version:Author Accepted Manuscript (After Peer Review)
    License:Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

  • Deciphering tumor ecosystems at super resolution from spatial transcriptomics with TESLA

    Deciphering tumor ecosystems at super resolution from spatial transcriptomics with TESLA
    Authors:Jian Hu, Emory UniversityKyle Coleman, University of PennsylvaniaDaiwei Zhang, University of PennsylvaniaEdward B Lee, University of PennsylvaniaHuman Kadara, The University of Texas MD Anderson Cancer CenterLinghua Wang, The University of Texas MD Anderson Cancer CenterMingyao Li, University of Pennsylvania
    Date:2023
    Publisher:CELL PRESS
    Publication Version:Author Accepted Manuscript (After Peer Review)
    License:Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

  • Functional HPV-specific PD-1(+) stem-like CD8 T cells in head and neck cancer

    Functional HPV-specific PD-1(+) stem-like CD8 T cells in head and neck cancer
    Authors:Christiane S Eberhardt, Emory UniversityHaydn Kissick, Emory UniversityMihir Patel, Emory UniversityMaria A Cardenas, Emory UniversityNataliya Prokhnevska, Emory UniversityRebecca Obeng, Emory UniversityTahseen H Nasti, Emory UniversityChristopher C Griffith, Emory UniversitySejin Im, Emory UniversityXu Wang, Emory UniversityDong Shin, Emory UniversityMary Carrington, National Cancer Institute, BethesdaZhuo G Chen, affiliationJohn Sidney, La Jolla Inst ImmunolAlessandro Sette, La Jolla Inst ImmunolNabil Saba, Emory UniversityAndreas Wieland, Emory UniversityRafi Ahmed, Emory University
    Date:2021
    Publisher:NATURE PORTFOLIO
    Publication Version:Author Accepted Manuscript (After Peer Review)

  • Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin

    Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin
    Authors:Rafee Talukder, University of WashingtonDimitrios Makrakis, University of WashingtonLeonidas N Diamantopoulos, University of PittsburghLucia Carril-Ajuria, Hospital Universitario 12 de OctubreDaniel Castellano, Hospital Universitario 12 de OctubreIvan De Kouchkovsky, University of California San FranciscoVadim S Koshkin, University of California San FranciscoJoseph J Park, University of MichiganAjjai Alva, University of MichiganMehmet Bilen, Emory UniversityTyler F Stewart, University of California San DiegoRana R McKay, University of California San DiegoVictor S Santos, University of UtahNeeraj Agarwal, University of UtahJayanshu Jain, University of IowaYousef Zakharia, University of IowaRafael Morales-Barrera, Universitat Autònoma de Barcelona, Barcelona, Spain.Michael E Devitt, University of VirginiaMichael Grant, Imperial College LondonMark P Lythgoe, Imperial College LondonDavid J Pinato, Imperial College LondonAriel Nelson, Seidman Cancer Center at Case Comprehensive Cancer Center, ClevelandChristopher J Hoimes, Seidman Cancer Center at Case Comprehensive Cancer Center, ClevelandEvan Shreck, Montefiore Medical CenterBenjamin A Gartrell, Montefiore Medical CenterAlex Sankin, Montefiore Medical CenterlexAbhishek Tripathi, University of Oklahoma Health Sciences CenterRoubini Zakopoulou, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.Aristotelis Bamias, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.Jure Murgic, University Hospital Center Sestre Milosrdnice, Zagreb, School of Dental Medicine, Zagreb, CroatiaAna Fröbe, Natl & Kapodistrian Univ AthensAlejo Rodriguez-Vida, Hospital del Mar Research Institute, Barcelona, Spain.Alexandra Drakaki, University of California Los AngelesSandy Liu, University of California Los AngelesVivek Kumar, Harvard Medical SchoolGiuseppe Di Lorenzo, Oncology University of Molise and ASL, Salerno, Italy.Monika Joshi, Penn State Cancer Institute, Hershey, PA.Pedro Isaacsson Velho, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MDLucia Alonso Buznego, Hospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain.Ignacio Duran, Hospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain.Marcus Moses, Hospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain.Pedro Barata, Tulane UniversityGuru Sonpavde, Harvard Medical SchoolEvan Y Yu, University of WashingtonJonathan L Wright, Fred Hutchinson Cancer Research Center, Seattle, WA.Petros Grivas, University of WashingtonAli Raza Khaki, University of Washington
    Date:2022
    Publisher:CIG MEDIA GROUP, LP
    Publication Version:Author Accepted Manuscript (After Peer Review)
    License:Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

  • Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

    Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
    Authors:Julie R Brahmer, Johns Hopkins Kimmel Cancer CenterJong-Seok Lee, National University Bundang HospitalTudor-Eliade Ciuleanu, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, RomaniaReyes Bernabe Caro, Instituto de Biomedicina de Seville, Seville, SpainMakoto Nishio, Cancer Institute Hospital of Japanese Foundation for Cancer ResearchLaszlo Urban, Matrai Gyogyintezet, Mátraháza, HungaryClarisse Audigier-Valette, Hôpital Sainte MusseLorena Lupinacci, Hospital Italiano De Buenos Aires, Buenos Aires, ArgentinaRandeep Sangha, Cross Cancer Institute, Edmonton, AB, CanadaAdam Pluzanski, Maria Sklodowska-Curie National Research Institute of OncologyJacobus Burgers, Netherlands Cancer InstituteMauricio Mahave, Instituto Oncológico Fundación Arturo López Pérez, Santiago, ChileSamreen Ahmed, University Hospitals of Leicester NHS TrustAdam J Schoenfeld, Weill Cornell Medical College, New YorkLuis G Paz-Ares, Univ Complutense & CiberOncMartin Reck, German Center for Lung Research, Lung ClinicHossein Borghaei, Fox Chase Cancer Center, PhiladelphiaKenneth J O'Byrne, Translational Research Institute and Queensland University of TechnologyRavi G Gupta, Bristol Myers SquibbJudith Bushong, Bristol Myers SquibbLi Li, Bristol Myers SquibbSteven I Blum, Bristol Myers SquibbLaura J Eccles, Bristol Myers SquibbSuresh Ramalingam, Emory University
    Date:2023
    Publisher:LIPPINCOTT WILLIAMS & WILKINS
    Publication Version:Final Published Version
    License:Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

  • A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer

    A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
    Authors:Kai Sun, Houston Methodist Neal Cancer CenterYitian Xu, Houston Methodist Research InstituteLicheng Zhang, Houston Methodist Research InstitutePolly Niravath, Houston Methodist Neal Cancer CenterJorge Darcourt, Houston Methodist Neal Cancer CenterTejal Patel, Houston Methodist Neal Cancer CenterBin S Teh, Houston Methodist Neal Cancer CenterAndrew M Farach, Houston Methodist Neal Cancer CenterCarlo Guerrero, Houston Methodist Neal Cancer CenterSunil Mathur, Houston Methodist Neal Cancer CenterMark A Sultenfuss, Houston Methodist HospitalNakul Gupta, Houston Methodist HospitalMary R Schwartz, Houston Methodist HospitalSusan L Haley, Houston Methodist HospitalSindhu Nair, Houston Methodist Neal Cancer CenterXiaoxian Li, Emory UniversityThi Truc Anh Nguyen, Emory UniversityJoseph D Butner, Houston Methodist Research InstituteJoe Ensor, Houston Methodist Neal Cancer CenterJaime A Mejia, Merck Res LabsZhuyong Mei, Baylor College of MedicineBrian E Butler, Houston Methodist HospShu-Hsia Chen, Houston Methodist Research InstituteEric H Bernicker, Houston Methodist Neal Cancer CenterJenny C Chang, Houston Methodist Neal Cancer Center
    Date:2022
    Publisher:AMER ASSOC CANCER RESEARCH
    Publication Version:Final Published Version
    License:Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

  • Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

    Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
    Authors:Fang Yang, Emory UniversityChloe Shay, Emory UniversityMarin Abousaud, Emory HealthcareChris Tang, Emory UniversityYamin Li, SUNY Upstate Medical UniversityZhaohui Qin, Emory UniversityNabil Saba, Emory UniversityYong Teng, Emory University
    Date:2023
    Publisher:BMC
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International

  • Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner

    Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner
    Authors:Michael Brandon Ware, Emory UniversityMaggie Phillips, Emory UniversityChristopher McQuinn, Ohio State UniversityMohammad Y. Zaidi, Emory UniversityHannah M. Knochelmann, Medical University of South CarolinaEmily Greene, Emory UniversityBrian Robinson, Emory UniversityCameron J. Herting, Emory UniversityThomas A. Mace, Ohio State UniversityZhengjia Chen, Emory UniversityChao Zhang, Emory UniversityMatthew R. Farren, Emory UniversityAmanda N. Ruggieri, Emory UniversityJacob S. Bowers, Medical University of South CarolinaReena Shakya, Ohio State UniversityAlton Farris III, Emory UniversityGregory Young, Ohio State UniversityWilliam E. Carson III, Ohio State UniversityBassel El-Rayes, Emory UniversityChrystal Paulos, Emory UniversityGregory Lesinski, Emory University
    Date:2023
    Publisher:AMER SOC CLINICAL INVESTIGATION INC
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International

  • Defining HPV-specific B cell responses in patients with head and neck cancer

    Defining HPV-specific B cell responses in patients with head and neck cancer
    Authors:Andreas Wieland, Emory UniversityMihir Patel, Emory UniversityMaria A Cardenas, Emory UniversityChristiane S Eberhardt, Emory UniversityWilliam Hudson, Emory UniversityRebecca Obeng, Emory UniversityChristopher C Griffith, Emory UniversityXu Wang, Emory UniversityZhuo G Chen, Emory UniversityHaydn Kissick, Emory UniversityNabil Saba, Emory UniversityRafi Ahmed, Emory University
    Date:2020
    Publisher:NATURE PORTFOLIO
    Publication Version:Author Accepted Manuscript (After Peer Review)